Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Glycobiology

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/glycob/cwq109PMID 20639190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding*

  2010cited by this paper
• The structural basis for catalytic function of GMD and RMD, two closely related enzymes from the GDP‐d‐rhamnose biosynthesis pathway

  2009cited by this paper
• Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

  2009cited by this paper
• Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

  2008cited by this paper
• GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans.

  2008cited by this paper
• Identification of the GDP‐N‐acetyl‐d‐perosamine producing enzymes from Escherichia coli O157:H7

  2008cited by this paper
• Mechanism and active site residues of GDP-fucose synthase.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• “Glyco‐peakfinder” – de novo composition analysis of glycoconjugates

  2007cited by this paper
• Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC

  2007cited by this paper
• Comparative and phylogenetic analysis of alpha-L-fucosidase genes.

  2007cited by this paper
• Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

  2007cited by this paper
• Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study.

  2007cited by this paper
• Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

  2007cited by this paper
• A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients

  2007cited by this paper
• Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC

  2006cited by this paper
• Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density

  2005cited by this paper
• IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

  2005cited by this paper
• Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity

  2004cited by this paper
• Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

  2004cited by this paper
• Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

  2004cited by this paper
• Crystal structure of a tetrameric GDP‐d‐mannose 4,6‐dehydratase from a bacterial GDP‐d‐rhamnose biosynthetic pathway

  2004cited by this paper
• Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism

  2004cited by this paper
• CONVERSION OF GDP-MANNOSE INTO VARIOUS GDP-DEOXYHEXOSES IN GRAM-NEGATIVE BACTERIA

  2003cited by this paper
• The biosynthesis of GDP-L-colitose: C-3 deoxygenation is catalyzed by a unique coenzyme B6-dependent enzyme.

  2003cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003cited by this paper
• Cloning and functional expression of a novel GDP-6-deoxy-D-talose synthetase from Actinobacillus actinomycetemcomitans.

  2003cited by this paper
• Functional expression of Pseudomonas aeruginosa GDP-4-keto-6-deoxy-D-mannose reductase which synthesizes GDP-rhamnose.

  2002cited by this paper
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002cited by this paper
• Identification of Two GDP-6-deoxy-d-lyxo-4-hexulose Reductases Synthesizing GDP-d-rhamnose in Aneurinibacillus thermoaerophilus L420-91T *

  2001influential reference
• The Structure of a Human Type III Fcγ Receptor in Complex with Fc*

  2001cited by this paper
• The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex

  2000cited by this paper
• The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.

  2000cited by this paper
• Structural and kinetic analysis of Escherichia coli GDP-mannose 4,6 dehydratase provides insights into the enzyme's catalytic mechanism and regulation by GDP-fucose.

  2000cited by this paper
• A bifunctional epimerase-reductase acts downstream of the MUR1 gene product and completes the de novo synthesis of GDP-L-fucose in Arabidopsis.

  2000cited by this paper
• Assays for antibody-dependent cell-mediated cytotoxicity (ADCC) and reverse ADCC (redirected cytotoxicity) in human natural killer cells.

  1999cited by this paper
• Structural and enzymatic characterization of human recombinant GDP‐D‐mannose‐4,6‐dehydratase

  1999cited by this paper
• Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

  1999cited by this paper
• Recent Advances in Carbohydrate Bioengineering

  1999cited by this paper
• Carbohydrate-active enzymes : an integrated database approach

  1999cited by this paper
• Identification of the Fucose Synthetase Gene in the Colanic Acid Gene Cluster of Escherichia coli K-12

  1998cited by this paper
• Molecular Cloning of Human GDP-mannose 4,6-Dehydratase and Reconstitution of GDP-fucose Biosynthesis in Vitro *

  1998cited by this paper
• The IgG Fc receptor family

  1998cited by this paper
• Expression, purification and characterization of GDP‐d‐mannose 4,6‐dehydratase from Escherichia coli

  1997cited by this paper
• IgE regulation : molecular mechanisms

  1997cited by this paper
• The use of osazones as matrices for the matrix-assisted laser desorption/ionization mass spectrometry of carbohydrates.

  1997cited by this paper
• IgG effector mechanisms.

  1996cited by this paper
• The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.

  1991cited by this paper
• Positive genetic selection for gene disruption in mammalian cells by homologous recombination.

  1989cited by this paper
• Immunoglobulin G as a glycoprotein.

  1986cited by this paper
• Effect of gamma rays at the dihydrofolate reductase locus: Deletions and inversions

  1986cited by this paper
• Study of the conversion of GDP-mannose into GDP-fucose in Nereids: a biochemical marker of oocyte maturation.

  1984cited by this paper
• Mechanisms of Activation of Human Natural Killer Cells Against Tumor and Virus‐infected Cells

  1979cited by this paper
• Isolation of two human tumor epithelial cell lines from solid breast carcinomas.

  1978cited by this paper
• Advances in Carbohydrate Chemistry and Biochemistry, Volume 33

  1977cited by this paper

• Integrating text mining and knowledge graph to enhance biopharmaceutical process optimization

  2026cites this paper
• Molecule Formats of B-Cell Targeting Biologics: Applications in Autoimmune Disease Treatment and Impacts on Manufacturability

  2025cites this paper
• Generation of Long-Lived CHO Cells Suitable for Production of Afucosylated Antibodies and Fc-Fusion Proteins

  2025cites this paper
• Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability

  2024cites this paper
• Application of fucosylation inhibitors for production of afucosylated antibody

  2024cites this paper
• A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models

  2024cites this paper
• Modulating antibody effector functions by Fc glycoengineering.

  2023cites this paper
• Cell factory engineering: Challenges and opportunities for synthetic biology applications

  2023cites this paper
• Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing

  2023cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• In planta expression of active bacterial GDP‐6‐deoxy‐d‐lyxo‐4‐hexulose reductase for glycan modulation

  2023cites this paper
• Sialylation as an Important Regulator of Antibody Function

  2022cites this paper
• Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation

  2022cites this paper
• New Opportunities in Glycan Engineering for Therapeutic Proteins

  2022cites this paper
• Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.

  2022cites this paper
• Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells.

  2022cites this paper
• Production of afucosylated antibodies in CHO cells by coexpression of an anti‐FUT8 intrabody

  2022cites this paper
• Coupling CRISPR interference with FACS enrichment: New approach in glycoengineering of CHO cell lines for therapeutic glycoprotein production

  2022cites this paper
• Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

  2021cites this paper
• On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions

  2021cites this paper
• Glycoengineering Chinese hamster ovary cells: a short history

  2021cites this paper
• Monoclonal Antibody Glycoengineering for Biopharmaceutical Quality Assurance

  2021cites this paper
• Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness

  2020cites this paper
• Mass spectrometric analysis of core fucosylation and sequence variation in a human-camelid monoclonal antibody.

  2020cites this paper
• Generation of FX −/− and Gmds −/− CHOZN host cell lines for the production of afucosylated therapeutic antibodies

  2020cites this paper
• Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors

  2020cites this paper
• Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies

  2020influential citation
• Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.

  2020cites this paper
• Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions

  2019cites this paper
• Glycoengineering of Antibodies for Modulating Functions.

  2019cites this paper
• Vector-related stratagems for enhanced monoclonal antibody production in mammalian cells.

  2019cites this paper
• Application of Genetic Engineering in Biotherapeutics Development

  2019cites this paper
• Metabolic engineering of CHO cells to prepare glycoproteins.

  2018cites this paper
• Antibody glycoengineering strategies in mammalian cells

  2018cites this paper
• Innovation in Cell Banking, Expansion, and Production Culture.

  2018cites this paper
• Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies.

  2018cites this paper
• A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies

  2018cites this paper
• The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

  2018cites this paper
• Modulation of IgG1 immunoeffector function by glycoengineering of the GDP‐fucose biosynthesis pathway

  2018cites this paper
• Optimization of Protein Expression in Mammalian Cells

  2018cites this paper
• mRNA as novel technology for passive immunotherapy

  2018cites this paper
• Allogeneic hematopoietic stem cell transplantation as immunotherapy: B lymphocytes versus leukemia

  2018cites this paper
• Glycosylation

  2018cites this paper
• In Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor

  2017cites this paper
• Engineer Medium and Feed for Modulating N-Glycosylation of Recombinant Protein Production in CHO Cell Culture.

  2017cites this paper
• Impact of IgG Fc‐Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy

  2017cites this paper
• Therapeutic glycoprotein production in mammalian cells.

  2017cites this paper
• Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development

  2017cites this paper
• Humanizing glycosylation pathways in eukaryotic expression systems

  2017cites this paper
• Influence of immunoglobulin G-glycan and subclass variation on antibody effector functions

  2017cites this paper
• Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

  2017cites this paper
• New Mammalian Expression Systems.

  2017cites this paper
• FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality

  2017cites this paper
• Advancement in bioprocess technology: parallels between microbial natural products and cell culture biologics

  2017cites this paper
• Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

  2017cites this paper
• Recombinant glycoproteins: The impact of cell lines and culture conditions on the generation of protein species.

  2016cites this paper
• Controlling the time evolution of mAb N‐linked glycosylation ‐ Part II: Model‐based predictions

  2016cites this paper
• ADCC Enhancement Technologies for Next‐Generation Therapeutic Antibodies

  2016cites this paper
• Optimizing the glycosylation of recombinant proteins

  2016cites this paper
• The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity.

  2016cites this paper
• Production d'IgG sialylées en CHO et impact sur leurs fonctions effectrices

  2016cites this paper
• Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans

  2016cites this paper
• Humanizing glycosylation pathways in eukaryotic expression systems

  2016cites this paper
• Harnessing Fc receptor biology in the design of therapeutic antibodies.

  2016cites this paper
• Applying Acylated Fucose Analogues to Metabolic Glycoengineering

  2015cites this paper
• (54) Title: COMPOSITIONS AND METHODS FOR REDUCING FUCOSYLATION OF GLYCOPROTEINS IN INSECT CELLS AND METHODS OF USE THEREOF FOR PRODUCTION RECOMBINANT GLYCOPROTEINS

  2015cites this paper
• Enhanced detection of in‐gel released N‐glycans by MALDI‐TOF‐MS

  2015cites this paper
• The art of CHO cell engineering: A comprehensive retrospect and future perspectives.

  2015cites this paper
• Glycosylation in Cell Culture

  2015cites this paper
• Cell line development for biomanufacturing processes: recent advances and an outlook

  2015influential citation
• Optimizing Chinese hamster ovary cell line development via targeted control of N-glycosylation

  2015cites this paper
• N-Glycosylation optimization of recombinant antibodies in CHO cell through process and metabolic engineering

  2015cites this paper
• An Overview and History of Glyco-Engineering in Insect Expression Systems.

  2015cites this paper
• Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

  2015cites this paper
• Regulation and Programming of Antibody Effector Function through IgG Glycosylation

  2014cites this paper
• Multifactorial aspects of antibody-mediated blood cell destruction

  2014cites this paper
• Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.

  2014cites this paper
• Minimizing fucosylation in insect cell‐derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy

  2014cites this paper
• Glycosylation analysis of Chinese hamster ovary produced glycoproteins

  2014cites this paper
• Large Scale Suspension Culture of Mammalian Cells

  2014cites this paper
• Process Development and Manufacturing of Therapeutic Antibodies

  2014cites this paper
• The choice of mammalian cell host and possibilities for glycosylation engineering.

  2014cites this paper
• A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.

  2014cites this paper
• Minimizing fucosylation in insect cell‐derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy

  2014cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2009–2010

  2014cites this paper
• Glycosylation and Fc receptors.

  2014cites this paper
• A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells.

  2014influential citation
• pregnancy A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in

  2014cites this paper
• Mammalian cell line developments in speed and efficiency.

  2014cites this paper
• CHO starter cell lines for manufacturing of proteins with pre-defined glycoprofiles

  2013cites this paper
• Comprehensive characterization of protein structures by liquid chromatography coupled with mass spectrometry (LC-MS)

  2013cites this paper
• Glycosylation patterns of human immunoglobulin G - recombinant IgG, vaccineinduced IgG and allo-immune specific IgG

  2013cites this paper
• Cell Culture‐Based Production

  2013cites this paper
• Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model

  2013cites this paper
• Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals

  2013cites this paper
• MONOCLONAL ANTIBODIES WITH ADCC AND CDC ENHANCEMENT FOR THERAPY

  2013cites this paper
• Charakterisierung des N-Glykosylierungsprofils der neuen Entenzelllinie AGE1.CR und die gerichtete Modifikation der Fucosylierung

  2012influential citation
• Fucose-targeted glycoengineering of pharmaceutical cell lines.

  2012cites this paper
• Glycoengineered Yeast as an Alternative Monoclonal Antibody Discovery and Production Platform

  2012cites this paper
• Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F.

  2012cites this paper